Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2093869 Target Snapshot

Integrin alpha-IIb/beta-3 · PROTEIN COMPLEX · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
2,360Compounds
398Assays
5Approved Drugs
3,187.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Integrin alpha-IIb/beta-3 shows approved-linked disease relevance led by myocardial infarction. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P05106. Start with myocardial infarction, then reuse UniProt P05106 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with myocardial infarction, then reuse UniProt P05106 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 3 linked drugs
Open source guide
Disease program
myocardial infarction

Integrin alpha-IIb/beta-3 shows approved-linked disease relevance led by myocardial infarction. 5 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.

Start review with myocardial infarction because it currently carries approved-linked support. Linked drugs include ABCIXIMAB, EPTIFIBATIDE, TIROFIBAN HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 3 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Integrin alpha-IIb/beta-3 as ChEMBL target CHEMBL2093869, mapped to UniProt P05106. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Integrin alpha-IIb/beta-3
PROTEIN COMPLEX · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2093869
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P05106
Integrin beta-3
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Integrin alpha-IIb/beta-3 is the right protein anchor across sources, using UniProt P05106 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why myocardial infarction is currently framed as approved-linked support. It currently carries 3 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameIntegrin alpha-IIb/beta-3
Target TypePROTEIN COMPLEX
OrganismHomo sapiens
UniProtP05106
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelIntegrin beta-3
UniProt AccessionP05106
Component TypeProtein
Sequence Length788 aa

Integrin beta-3

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Integrin alpha-IIb/beta-3, mapped to UniProt P05106. ChEMBL maps the protein component as Integrin beta-3. Sequence length is 788 aa.

Mapped IDP05106
Review nameIntegrin alpha-IIb/beta-3
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Integrin alpha-IIb/beta-3 shows approved-linked disease relevance led by myocardial infarction. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
myocardial infarction
3 linked drugs · 3 direct · 3 efficacy
Linked drugABCIXIMAB
Linked drugEPTIFIBATIDE
Linked drugTIROFIBAN HYDROCHLORIDE
Approved-linked Approved
acute myocardial infarction
2 linked drugs · 2 direct · 2 efficacy
Linked drugABCIXIMAB
Linked drugEPTIFIBATIDE
Approved-linked Approved
intermediate coronary syndrome
2 linked drugs · 2 direct · 2 efficacy
Linked drugABCIXIMAB
Linked drugEPTIFIBATIDE
Approved-linked Approved
Recurrent thrombophlebitis
2 linked drugs · 2 direct · 2 efficacy
Linked drugABCIXIMAB
Linked drugEPTIFIBATIDE
Approved-linked Approved
acute coronary syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugEPTIFIBATIDE
Late clinical Phase III
ST Elevation Myocardial Infarction
3 linked drugs · 3 direct · 3 efficacy
Linked drugABCIXIMAB
Linked drugEPTIFIBATIDE
Linked drugZALUNFIBAN
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with myocardial infarction because it currently carries approved-linked support. Linked drugs include ABCIXIMAB, EPTIFIBATIDE, TIROFIBAN HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasemyocardial infarction
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

5
Approved
2
Phase III
12
Phase II
Assay Mix

Activity Type Distribution

IC502,843.0
KI204.0
EC5023.0
KD117.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL315008 10.8 IC50 0.016 Preclinical
CHEMBL293601 10.64 Kd 0.023 Preclinical
CHEMBL1782661 10.64 IC50 0.023 Preclinical
CHEMBL80432 10.59 Kd 0.026 Preclinical
CHEMBL421547 10.57 IC50 0.027 Preclinical
CHEMBL329015 10.39 IC50 0.041 Preclinical
CHEMBL329871 10.37 IC50 0.043 Preclinical
CHEMBL8572 10.33 Ki 0.0465 Preclinical
CHEMBL57040 10.25 Kd 0.056 Preclinical
CHEMBL88944 10.24 IC50 0.057 Preclinical
Distribution

pChEMBL Value Distribution

254
5.0
218
5.5
282
6.0
352
6.5
358
7.0
303
7.5
217
8.0
163
8.5
85
9.0
45
9.5
pChEMBL
Approved Drugs

Approved Drugs

TIROFIBAN
CHEMBL916
Approved 1998
Properties Compare Identifier
EPTIFIBATIDE
CHEMBL1174
Approved 1998
Properties Compare Identifier
Assay Landscape

Assay Landscape

398
Total Assays
1,507
Tested Compounds
3
Assay Types
Binding — 239 assays, 1,507 compounds
BAO Format Assays Compounds Avg pChEMBL
protein complex format 144 1,087 7.0
assay format 72 325 7.0
cell-free format 12 81 6.1
cell-based format 9 9 7.8
tissue-based format 2 5 7.4
Functional — 157 assays, 865 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 94 489 6.6
cell-free format 40 351 6.1
organism-based format 16 22 7.7
cell-based format 7 3 5.0
ADME — 2 assays, 3 compounds
BAO Format Assays Compounds Avg pChEMBL
protein complex format 2 3 7.1

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine